Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Shigella sonnei 53G

Phase 1Biologic

1

Indications

5

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Infection

NCT05959616

Clinical

Trials by Indication[1]

Shigella2 trials

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

Completed·PPATH·Phase 1·NCT02816346·56 enrolled

Shigella WRSS1 Vaccine Trial in Bangladesh

Completed·PPATH·Phase 1·NCT02934178·16 enrolled

Infection2 trials

Controlled Human Infection Model Challenge/Rechallenge

Completed·PPATH·Phase 1·NCT04992520·46 enrolled

Shigella Sonnei 53G Human Infection Study in Kenyan Adults

Recruiting·UUniversity of Oxford·Phase 1·NCT05959616·70 enrolled

Immunogenicity1 trial

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

Withdrawn·PPATH·Phase 2·NCT03038243

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Shigella sonnei 53G. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Shigella sonnei 53G compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Shigella sonnei 53G. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PATH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPATH

Related News